These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 17436351)

  • 1. Structure-based calculation of binding affinities of alpha 2A-adrenoceptor agonists.
    Balogh B; Hetényi C; Keseru MG; Mátyus P
    ChemMedChem; 2007 Jun; 2(6):801-5. PubMed ID: 17436351
    [No Abstract]   [Full Text] [Related]  

  • 2. 3D QSAR models for alpha2a-adrenoceptor agonists.
    Balogh B; Jójárt B; Wágner Z; Kovács P; Máté G; Gyires K; Zádori Z; Falkay G; Márki A; Viskolcz B; Mátyus P
    Neurochem Int; 2007 Oct; 51(5):268-76. PubMed ID: 17643557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies.
    Yuzlenko O; Kieć-Kononowicz K
    J Comput Chem; 2009 Jan; 30(1):14-32. PubMed ID: 18496794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medetomidine analogs as alpha 2-adrenergic ligands. 3. Synthesis and biological evaluation of a new series of medetomidine analogs and their potential binding interactions with alpha 2-adrenoceptors involving a "methyl pocket".
    Zhang X; De Los Angeles JE; He MY; Dalton JT; Shams G; Lei L; Patil PN; Feller DR; Miller DD; Hsu FL
    J Med Chem; 1997 Sep; 40(19):3014-24. PubMed ID: 9301663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular modelling of subtypes (alpha(2A), alpha(2B) and alpha(2C)) of alpha(2)-adrenoceptors: a comparative study.
    Balogh B; Szilágyi A; Gyires K; Bylund DB; Mátyus P
    Neurochem Int; 2009 Nov; 55(6):355-61. PubMed ID: 19447153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alpha(2A)-adrenergic versus imidazoline receptor controversy in rilmenidine's action: alpha(2A)-antagonism in humans versus alpha(2A)-agonism in rabbits.
    Molderings GJ; Bonisch H; Bruss M; Gothert M
    Ann N Y Acad Sci; 2003 Dec; 1009():279-82. PubMed ID: 15028600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The unique nature of the serine interactions for alpha 1-adrenergic receptor agonist binding and activation.
    Hwa J; Perez DM
    J Biol Chem; 1996 Mar; 271(11):6322-7. PubMed ID: 8626427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding site analysis of full-length alpha1a adrenergic receptor using homology modeling and molecular docking.
    Pedretti A; Elena Silva M; Villa L; Vistoli G
    Biochem Biophys Res Commun; 2004 Jun; 319(2):493-500. PubMed ID: 15178433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computer aided comparative analysis of the binding modes of the adenosine receptor agonists for all known subtypes of adenosine receptors.
    Ivanov AA; Palyulin VA; Zefirov NS
    J Mol Graph Model; 2007 Jan; 25(5):740-54. PubMed ID: 17095272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence resonance energy transfer analysis of alpha 2a-adrenergic receptor activation reveals distinct agonist-specific conformational changes.
    Zürn A; Zabel U; Vilardaga JP; Schindelin H; Lohse MJ; Hoffmann C
    Mol Pharmacol; 2009 Mar; 75(3):534-41. PubMed ID: 19106230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequence analysis reveals how G protein-coupled receptors transduce the signal to the G protein.
    Oliveira L; Paiva PB; Paiva AC; Vriend G
    Proteins; 2003 Sep; 52(4):553-60. PubMed ID: 12910455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zn-alpha2-glycoprotein, an MHC class I-related glycoprotein regulator of adipose tissues: modification or abrogation of ligand binding by site-directed mutagenesis.
    McDermott LC; Freel JA; West AP; Bjorkman PJ; Kennedy MW
    Biochemistry; 2006 Feb; 45(7):2035-41. PubMed ID: 16475792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homology modelling and binding site mapping of the human histamine H1 receptor.
    Kiss R; Kovári Z; Keseru GM
    Eur J Med Chem; 2004 Nov; 39(11):959-67. PubMed ID: 15501545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular evolution of adrenoceptors and dopamine receptors: implications for the binding of catecholamines.
    Xhaard H; Rantanen VV; Nyrönen T; Johnson MS
    J Med Chem; 2006 Mar; 49(5):1706-19. PubMed ID: 16509586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of the first transmembrane segment of human α(2) -adrenoceptors in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine.
    Laurila JM; Wissel G; Xhaard H; Ruuskanen JO; Johnson MS; Scheinin M
    Br J Pharmacol; 2011 Nov; 164(5):1558-72. PubMed ID: 21649638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-dimensional models of alpha(2A)-adrenergic receptor complexes provide a structural explanation for ligand binding.
    Salminen T; Varis M; Nyrönen T; Pihlavisto M; Hoffrén AM; Lönnberg T; Marjamäki A; Frang H; Savola JM; Scheinin M; Johnson MS
    J Biol Chem; 1999 Aug; 274(33):23405-13. PubMed ID: 10438518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening.
    Evers A; Klebe G
    Angew Chem Int Ed Engl; 2004 Jan; 43(2):248-51. PubMed ID: 14695622
    [No Abstract]   [Full Text] [Related]  

  • 18. Homology modeling of MT1 and MT2 receptors.
    Farce A; Chugunov AO; Logé C; Sabaouni A; Yous S; Dilly S; Renault N; Vergoten G; Efremov RG; Lesieur D; Chavatte P
    Eur J Med Chem; 2008 Sep; 43(9):1926-44. PubMed ID: 18255198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Concentration of mRNA of alpha-2A-adrenergic receptors and the number of specific binding sites for their agonists in regions of the brain].
    Dygalo NN; Kalinina TS; Surnina NIu; Nosova AV; Shishkina GT
    Dokl Akad Nauk; 1999 Jan; 364(3):417-9. PubMed ID: 10188097
    [No Abstract]   [Full Text] [Related]  

  • 20. Model structures of alpha-2 adrenoceptors in complex with automatically docked antagonist ligands raise the possibility of interactions dissimilar from agonist ligands.
    Xhaard H; Nyrönen T; Rantanen VV; Ruuskanen JO; Laurila J; Salminen T; Scheinin M; Johnson MS
    J Struct Biol; 2005 May; 150(2):126-43. PubMed ID: 15866736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.